Table IV.

Characteristics of patients who achieved CR/CRp as best response in either part of the trial (n = 8).

Characteristic	n
T-ALL Phenotype	1
Cytogenetics
Diploid	2
Ph+	0
−5/−7	2
Other	4
Prior therapies, median (range)	2 (1–4)
Prior decitabine	4
Prior response to decitabine	1 mCR
Prior Hyper-CVAD	5
Prior response to Hyper-CVAD	2 CR, 3 NR

n, number; T-ALL, T-cell acute lymphoblastic leukaemia; Ph+, Philadelphia chromosome-positive; −5/−7, deletion of chromosome 5 and/or 7; CR, complete response; CRp, complete response without recovery of platelets; mCR, complete marrow response; Hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose methotrexate and cytarabine.